Zackery P. Bulman
Assistant Professor, College of Pharmacy - Pharmacy Practice
Contact
Office Phone:
Email:
Related Sites:
About Heading link
Research Interests:
The medical community is at a constant state of war with bacteria to both prevent and overcome antimicrobial resistance, which is one of the largest threats to global health. The frequency and nature of bacterial cell replication combined with the widespread use of antibiotics suggests that antimicrobial resistance is likely to persist. Dr. Bulman’s laboratory investigates novel pharmacotherapeutic approaches that aim to overcome drug resistant bacteria and improve patient outcomes.
Teaching and Supervision Heading link
Applied Research Methods (PMPR 376), 1/9/2023 – 4/28/2023
Undergrad Resrch Pharm Pract (PMPR 380), 8/22/2022 – 12/2/2022
Pharmacokinetics (PHAR 435), 8/22/2022 – 12/2/2022
Pharmacokinetics (PHAR 435), 8/22/2022 – 12/2/2022
Undergrad Resrch Pharm Pract (PMPR 380), 1/10/2022 – 4/29/2022
Applied Research Methods (PMPR 376), 1/10/2022 – 4/29/2022
Pathophysiology, Drug Action, & Therapeutics (PDAT) 6: Infectious Diseases (PHAR 506), 1/1/2022 – 5/6/2022
Pharmacokinetics (PHAR 435), 8/23/2021 – 12/3/2021
Pharmacokinetics (PHAR 435), 8/23/2021 – 12/3/2021
Selected Grants
Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniae, National Institutes of Health (National Institute of Allergy and Infectious Diseases)., 12/5/2022 - 11/30/2027, Obligated Amount: $783889; Anticipated Amount: $3660946
Selected Publications
Bulman, ZP, Wicha, SG, Nielsen, EI, Lenhard, JR, Nation, RL, Theuretzbacher, U, Derendorf, H, Tängdén, T, Zeitlinger, M, Landersdorfer, CB, Bulitta, JB, Friberg, LE, Li, J, Tsuji, BT. (2022). Research priorities towards precision antibiotic therapy to improve patient care. The Lancet Microbe, 3, (10), e795-e802. doi:10.1016/S2666-5247(22)00121-5.
Smith, NM, Boissonneault, KR, Chen, L, Petraitis, V, Petraitiene, R, Tao, X, Zhou, J, Lang, Y, Kavaliauskas, P, Bulman, ZP, Holden, PN, Cha, R, Bulitta, JB, Kreiswirth, BN, Walsh, TJ, Tsuji, BT. (2022). Mechanistic Insights to Combating NDM- And CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity. Antimicrobial Agents and Chemotherapy, 66, (9). doi:10.1128/aac.00527-22.
Wences, M, Wolf, ER, Li, C, Singh, N, Bah, N, Tan, X, Huang, Y, Bulman, ZP. (2022). Combatting Planktonic and Biofilm Populations of Carbapenem-Resistant Acinetobacter baumannii with Polymyxin-Based Combinations. Antibiotics, 11, (7). doi:10.3390/antibiotics11070959.
Huang, Y, Rana, AP, Wenzler, E, Ozer, EA, Krapp, F, Bulitta, JB, Hauser, AR, Bulman, ZP. (2022). Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 77, (2), 356-363. doi:10.1093/jac/dkab381.
Bulman, ZP, Tan, X, Chu, TY, Huang, Y, Rana, AP, Singh, N, Flowers, SA, Kyono, Y, Kreiswirth, BN, Chen, L. (2022). Ceftazidime-avibactam based combinations against carbapenemase producing Klebsiella pneumoniae harboring hypervirulence plasmids. Computational and Structural Biotechnology Journal, 20, 3946-3954. doi:10.1016/j.csbj.2022.07.017.
McMurtry, TA, Barekat, A, Rodriguez, F, Purewal, P, Bulman, ZP, Lenhard, JR. (2021). Capability of Enterococcus faecalis to shield Gram-negative pathogens from aminoglycoside exposure. Journal of Antimicrobial Chemotherapy, 76, (10), 2610-2614. doi:10.1093/jac/dkab211.
Huang, Y, Sokolowski, K, Rana, A, Singh, N, Wang, J, Chen, K, Lang, Y, Zhou, J, Kadiyala, N, Krapp, F, Ozer, EA, Hauser, AR, Li, J, Bulitta, JB, Bulman, ZP. (2021). Generating genotype-specific aminoglycoside combinations with ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 65, (9). doi:10.1128/AAC.00692-21.
Bulman, ZP, Krapp, F, Pincus, NB, Wenzler, E, Murphy, KR, Qi, C, Ozer, EA, Hauser, AR. (2021). Genomic features associated with the degree of phenotypic resistance to carbapenems in carbapenem-resistant klebsiella pneumoniae. mSystems, 6, (5). doi:10.1128/mSystems.00194-21.
Huang, Y, Wu, T, Perez, O, Rana, AP, Chen, L, Kreiswirth, BN, Satlin, MJ, Bulman, ZP. (2021). In vitro Optimization of Ceftazidime/Avibactam for KPC-Producing Klebsiella pneumoniae. Frontiers in Microbiology, 12. doi:10.3389/fmicb.2021.618087.
Professional Leadership
ACCP ID PRN Nominations Committee, American College of Clinical Pharmacy, 1/1/2022 - 12/31/2022
SIDP Website Committee, Society for Infectious Diseases Pharmacists, 11/1/2021 - 10/31/2022
PhD Thesis External Reviewer, 6/18/2021 - 8/31/2021
ISAC Anti-Infective Pharmacology Working Group, 12/2/2019 - Present
SIDP Website Committee, 11/25/2019 - 10/29/2021
ISAP Treasurer, International Society of Anti-Infective Pharmacology, 2018 - Present
Notable Honors
2022, ACCP RI Student Futures Grant Mentor, American College of Clinical Pharmacy
2020, FISAC, International Society of Antimicrobial Chemotherapy
2020, Hans W. Vahlteich Research Scholar,
2018, ACCP RI Student Futures Grant Mentor, American College of Clinical Pharmacy
2016, IDWeek Trainee Award, Infectious Diseases Society of America
2016, ASM Microbe Travel Award, American Society for Microbiology
2015, ICAAC Infectious Diseases Fellows Grant, American Society for Microbiology
2015, Wolters Kluwer Award for Scientific Communication, School of Pharmacy
2015, Daniel H. Murray Memorial Professional Development Award, Daniel H. Murray Memorial
Education
Degrees:
PharmD, University at Buffalo, State University of New York, United States, 2015
B.S., Rochester Institute of Technology, United States, 2011
Postgraduate Training:
Infectious Diseases Pharmacology Fellowship, University at Buffalo, State University of New York, United States, 2017
Clinical and Translational Research Fellow, VA Western New York Healthcare System, United States, 2017
Selected Presentations
Singh, N, Poggensee, L, Huang, Y, Evans, CT, Suda, KJ, Bulman, ZP. (2022 June 01). Antibiotic susceptibility patterns of viridans group streptococci isolates in the United States from 2010 to 2020. doi:10.1093/jacamr/dlac049.
Bulman, Zackery. (2021 December 17). Genotype specific combination treatment strategies to thwart KPC-producing K. pneumoniae. Antimicrobial Resistance Symposium. Beijing, China [Virtual Seminar].
Bulman, Zackery, Rao, Gauri, Velkov, Tony. (2021 November 05). Meet the Editors: Zackery Bulman, Gauri Rao, and Tony Velkov. Chinese Agricultural University Infectious Diseases Symposium. Beijing, China [Virtual Seminar].
Dudley, Mike, Bulman, Zackery, Rao, Gauri. (2021 October 26). It Takes Two to Tango: PK-PD Considerations for Beta-lactamase Inhibitor Combinations for Drug Resistant Pathogens. Anti-Infective Working Group Seminar Series.